Anzeige
Meldung des Tages: Warum Kupfer und Silber aus Nevada plötzlich wieder im Fokus stehen könnten
Werbung
Attraktive Knock-Outs auf AbbVie Inc
Typ Hebel Bid / Ask WKN
Call
4,8 3,83 € / 3,85 €
SX7T95
Typ Hebel Bid / Ask WKN
Put
4,8 3,81 € / 3,83 €
SX14P0
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf AbbVie Inc

AbbVie Aktie News

Aktie
WKN:  A1J84E ISIN:  US00287Y1091 US-Symbol:  ABBV Branche:  Pharmazeutika Land:  USA
219,34 $
-4,59 $
-2,05%
183,86 € 19:18:51 Uhr
Depot/Watchlist
Marktkapitalisierung *
345,80 Mrd. €
Streubesitz
24,69%
KGV
21,69
Dividende
6,56 $
Dividendenrendite
3,38%
neu: Nachhaltigkeits-Score
46 %
Index-Zuordnung
S&P 500
Weiter abwärts? Short handeln - Jetzt mit Hebel 5,16: VH3ME4
Werbung

AbbVie News

27.05.25 - PR Newswire
AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio
AbbVie Features New Data Across Difficult-​to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio PR Newswire
22.05.25 - PR Newswire
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - ABBV
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - ABBV PR Newswire
19.05.25 - PR Newswire
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact The Gross Law Firm about pending Class Action - ABBV
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact The Gross Law Firm about pending Class Action - ABBV PR Newswire
16.05.25 - PR Newswire
June 3, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ABBV
June 3, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ABBV PR Newswire
14.05.25 - PR Newswire
U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression
U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-​tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression ...
14.05.25 - PR Newswire
AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas
AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-​Generation siRNA Therapies Across Multiple Therapeutic Areas PR ...
13.05.25 - PR Newswire
Investors who lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact Levi & Korsinsky about pending Class Action - ABBV
Investors who lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact Levi & Korsinsky about pending Class Action - ABBV PR Newswire
12.05.25 - PR Newswire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc.(ABBV) Shareholders
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc.(ABBV) Shareholders PR Newswire
09.05.25 - PR Newswire
Cerevel Therapeutics Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - ABBV
Cerevel Therapeutics Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - ABBV PR Newswire
09.05.25 - wallstreetONLINE Redaktion
Ihre wichtigsten Termine: Heute im Fokus: Commerzbank, AbbVie, Colgate-Palmolive, Krones, Bechtle und PNE
Gut geplant in den Tag. Mit dem wO-​Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine ...
08.05.25 - PR Newswire
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) - June 3, 2025 Deadline to Join - Contact The Gross Law Firm
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) - June 3, 2025 Deadline to Join - Contact The Gross Law Firm PR Newswire
06.05.25 - PR Newswire
AbbVie to Present at the Bank of America Securities Healthcare Conference
AbbVie to Present at the Bank of America Securities Healthcare Conference PR Newswire
06.05.25 - PR Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV PR Newswire
05.05.25 - PR Newswire
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors - Contact The Gross Law Firm
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors - Contact The Gross Law Firm PR Newswire
01.05.25 - PR Newswire
BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project"
BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project" PR Newswire
01.05.25 - PR Newswire
June 3, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ABBV
June 3, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ABBV PR Newswire
29.04.25 - PR Newswire
RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)
RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA) PR Newswire
29.04.25 - PR Newswire
Levi & Korsinsky Reminds Cerevel Therapeutics Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - ABBV
Levi & Korsinsky Reminds Cerevel Therapeutics Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - ABBV PR Newswire
28.04.25 - PR Newswire
Shareholders of Cerevel Therapeutics Holdings, Inc. Should Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - ABBV
Shareholders of Cerevel Therapeutics Holdings, Inc. Should Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - ABBV PR Newswire
25.04.25 - wallstreetONLINE Redaktion
Geschäftszahlen: AbbVie überrascht mit Quartals­zahlen: So viel Gewinn hat niemand erwartet!
AbbVie hat am Freitag seine Ergebnisse für das erste Quartal veröffentlicht. Das Biopharma-​Unternehmen liefert knackige Zahlen. Das freut die Anleger!Das Unternehmen meldet ...

Newssuche

Videos

newspaper
27.01.26 +0,22%
Technical Trading: Pfund Short
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »